How Have the Numbers Shaped Up for NYSE:DNMR, NASDAQ:VINC, NASDAQ:ARPO, NASDAQ:BLCM

DANIMER SCIENTIFIC (NYSE:DNMR) EARNINGS INFORMATION (NYSE:DNMR)

Danimer Scientific last posted its quarterly earnings data on March 29th, 2021. The reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $12.03 million for the quarter. Danimer Scientific has generated $0.00 earnings per share over the last year. Danimer Scientific has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.

IS DANIMER SCIENTIFIC A BUY RIGHT NOW? (NYSE:DNMR)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Danimer Scientific in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” Danimer Scientific stock.
Danimer Scientific

VINCERX PHARMA (NASDAQ:VINC) EARNINGS INFORMATION (NASDAQ:VINC)

Vincerx Pharma last released its quarterly earnings results on May 16th, 2021. The reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.14. Vincerx Pharma has generated $0.00 earnings per share over the last year.

IS VINCERX PHARMA A BUY RIGHT NOW? (NASDAQ:VINC)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Vincerx Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” Vincerx Pharma stock.
Vincerx Pharma

AERPIO PHARMACEUTICALS (NASDAQ:ARPO) EARNINGS INFORMATION (NASDAQ:ARPO)

Aerpio Pharmaceuticals last announced its quarterly earnings results on May 16th, 2021. The reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Aerpio Pharmaceuticals has generated ($0.53) earnings per share over the last year. Aerpio Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 11th, 2021 based off prior year’s report dates.

IS AERPIO PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:ARPO)

2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Aerpio Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Aerpio Pharmaceuticals stock.
Aerpio Pharmaceuticals

BELLICUM PHARMACEUTICALS (NASDAQ:BLCM) EARNINGS INFORMATION (NASDAQ:BLCM)

Bellicum Pharmaceuticals last posted its earnings results on May 17th, 2021. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.29. Bellicum Pharmaceuticals has generated ($19.91) earnings per share over the last year. Bellicum Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 5th, 2021 based off prior year’s report dates.

IS BELLICUM PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:BLCM)

2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Bellicum Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Bellicum Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
Bellicum Pharmaceuticals